XNAS · Healthcare · Biotechnology
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.17 | -0.21 | -23.53% | $0 | ❌ Miss | +1.83% | -5.45% | -17.51% |
| 2026-03-24 | Q4 2025 | -0.20 | -0.06 | +70.00% | $0 | ✅ Beat | +3.38% | +0.41% | -2.90% |
| 2025-11-12 |
| Q3 2025 |
| -0.25 |
| -0.24 |
| +4.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | — | -0.40 | — | $0 | — | +0.56% | +11.90% | +26.19% |
| 2025-03-26 | Q4 2024 | -0.87 | -0.25 | +71.26% | $0 | ✅ Beat | +5.10% | -10.98% | -22.75% |
| 2024-11-13 | Q3 2024 | — | -0.61 | — | $0 | — | -14.26% | -15.32% | -11.49% |
| 2024-08-13 | Q2 2024 | — | -0.88 | — | $3,000 | — | -1.89% | +26.14% | +7.20% |
| 2024-05-14 | Q1 2024 | 0.00 | -1.35 | -100.00% | $55,000 | ❌ Miss | +0.98% | +2.53% | -38.55% |
Showing last 8 quarters.